Logo Logo
Help
Contact
Switch Language to German
Kommoss, Stefan; Winterhoff, Boris; Oberg, Ann L.; Konecny, Gottfried E.; Wang, Chen; Riska, Shaun M.; Fan, Jian-Bing; Maurer, Matthew J.; April, Craig; Shridhar, Viji; Kommoss, Friedrich; Bois, Andreas du; Hilpert, Felix; Mahner, Sven; Baumann, Klaus; Schröder, Willibald; Burges, Alexander; Canzler, Ulrich; Chien, Jeremy; Embleton, Andrew C.; Parmar, Mahesh; Kaplan, Richard; Perren, Timothy; Hartmann, Lynn C.; Goode, Ellen L.; Dowdy, Sean C.; Pfisterer, Jacobus (2017): Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes. In: Clinical Cancer Research, Vol. 23, No. 14: pp. 3794-3801
Full text not available from 'Open Access LMU'.

Abstract

Purpose: Recent progress in understanding the molecular biology of epithelial ovarian cancer has not yet translated into individualized treatment for these women or improvements in their disease outcome. Gene expression has been utilized to identify distinct molecular subtypes, but there have been no reports investigating whether or not molecular subtyping is predictive of response to bevacizumab in ovarian cancer. Experimental Design: DASL gene expression arrays were performed on FFPE tissue from patients enrolled on the ICON7 trial. Patients were stratified into four TCGA molecular subtypes. Associations between molecular subtype and the efficacy of randomly assigned therapy with bevacizumab were assessed. Results: Molecular subtypes were assigned as follows: 122 immunoreactive (34%), 96 proliferative (27%), 73 differentiated (20%), and 68 mesenchymal (19%). In univariate analysis patients with tumors of proliferative subtype obtained the greatest benefit from bevacizumab with a median PFS improvement of 10.1 months [HR, 0.55 (95% CI, 0.34-0.90), P = 0.016]. For the mesenchymal subtype, bevacizumab conferred a nonsignificant improvement in PFS of 8.2 months [HR 0.78 (95% CI, 0.44-1.40), P = 0.41]. Bevacizumab conferred modest improvements in PFS for patients with immunoreactive subtype (3.8 months;P = 0.08) or differentiated subtype (3.7 months;P = 0.61). Multivariate analysis demonstrated significant PFS improvement in proliferative subtype patients only [HR, 0.45 (95% CI, 0.27-0.74), P = 0.0015]. Conclusions: Ovarian carcinoma molecular subtypes with the poorest survival (proliferative and mesenchymal) derive a comparably greater benefit from treatment that includes bevacizumab. Validation of our findings in an independent cohort could enable the use of bevacizumab for those patients most likely to benefit, thereby reducing side effects and healthcare cost. (C) 2017 AACR.